ALXO insider trading
HealthcareALX ONCOLOGY HOLDINGS INC — scored insider trade history from SEC Form 4 filings, parsed and contextualised by FilingIQ.
About ALX ONCOLOGY HOLDINGS INC
ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents, including ASPEN-06, under Phase 2 clinical study for treating Gastric/GEJ cancer; ASPEN-07, under Phase 1 clinical study for treating urothelial cancer; and ASPEN-03 and ASPEN-04, both under Phase 2 clinical study for treating head and neck squamous cell carcinoma. It has collaboration agreement for Evorpacept combination programs comprising Jazz Pharmaceuticals plc for zanidatamab, under Phase 1 trial for the treatment of breast cancer and other solid tumors; Quantum Leap Healthcare collaborative with an ADC, fam-trastuzumab deruxtecan-nxki, under Phase 1 trial for the treatment of patients with breast cancer; MD Anderson Cancer Center with rituximab and lenalidomide for the treatment of patients with indolent and aggressive NHL; Sanofi with isatuximab and dexamethasone, under Phase 1/2 trial for the treatment of patients with relapsed or refractory multiple myeloma; Academic Gastrointestinal Cancer Symposium; and University of Pittsburgh with liposomal doxorubicin and pembrolizumab, under Phase 2 trial recurrent platinum-resistant ovarian cancer. In addition, the company has collaboration agreement with Tallac Therapeutics, Inc. for the development of ALTA-002, a potent immune activator targeted to myeloid cells in the tumor to promote innate and adaptive anti-cancer immune responses. It has license agreements with Board of Trustees of the Leland Stanford Junior University, Selexis SA, and Crystal Bioscience, Inc. The company was incorporated in 2015 and is headquartered in South San Francisco, California.
Company website: www.alxoncology.com
ALXO insider activity at a glance
FilingIQ has scored 288 insider transactions for ALXO since Jul 21, 2020. The most recent filing in our index is dated Apr 16, 2026.
Across the full history, 22 open-market purchases
and 185 open-market sales
were filed under transaction codes P and S respectively. Compensatory share awards
(code A) and option exercises (code M) are tracked separately and not counted here.
The average FilingIQ composite score on ALXO insider trades is 54.1/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.
Other Healthcare tickers with recent insider activity
Frequently asked
- How many insider trades does FilingIQ track for ALXO?
- FilingIQ tracks 288 Form 4 insider transactions for ALXO (ALX ONCOLOGY HOLDINGS INC), covering filings from Jul 21, 2020 onwards. 7 of those were filed in the last 90 days.
- Are ALXO insiders net buyers or net sellers?
- Across the full Form 4 history for ALXO, 22 transactions (8%) were open-market purchases and 185 (64%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
- Where does ALXO insider data come from?
- Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.
- What sector is ALXO in?
- ALX ONCOLOGY HOLDINGS INC (ALXO) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $290.60M.
Methodology & sources
Every ALXO insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.